Curcumin - Theravalues

Drug Profile

Curcumin - Theravalues

Alternative Names: CR-011L; Curcumin nanoparticles; Theracurmin; Theracurmin CR-011L

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravalues Corporation
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Immunosuppressants; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Left ventricular hypertrophy
  • Phase I/II Cognition disorders
  • No development reported Cancer; Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (PO, Liquid)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer(Second-line therapy or greater) in USA (PO, Liquid)
  • 01 Oct 2017 Theravalues completes a phase I/II trial in Cognition disorders in USA (PO) (NCT02104752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top